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Perivascular epithelioid cell tumor (PEComa) is a rare subtype of soft tissue sarcoma that coexpresses
melanocytic and smooth muscle markers. We report a case of malignant PEComa arising from the
gastrointestinal tract. Deﬁnitive diagnosis of malignant PEComa is based on pathological examination
and the standard treatment is complete surgical resection. Cytotoxic chemotherapy has limited efﬁcacy
in recurrent or metastatic malignant PEComa. Overactivation of the mammalian target of rapamycin
(mTOR) pathway is observed in PEComa, and mTOR inhibitors have been recommended as an effective
systemic treatment.
Copyright © 2015, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Perivascular epithelioid cell tumor (PEComa), a rare subtype of
mesenchymal neoplasm, is composed of perivascular epithelioid
cells that coexpress myogenic and melanocytic markers on
immunohistochemical staining.1 Bonetti et al. initially described
these distinctive cells in 1992.2 Currently, the family of PEComas
includes angiomyolipoma (AML), pulmonary lymphangioleiomyo-
matosis (LAM), clear cell sugar tumor of the lung, extrapulmonary
clear cell sugar tumor, and clear cell myomelanocytic tumor.3
Although rare, PEComas have been reported in a variety of
anatomical locations and are considered to be ubiquitous.4 The
clinical behavior of PEComas is highly heterogeneous. Most are
benign and are cured by surgical resection,5 but aminority recurs or
metastasizes. Thus, various deﬁnitions of the malignant potential of
these tumors have been proposed.1,3,6 PEComa patients have been
treated with conventional chemotherapy used in other types of
sarcoma. However, recognition of aberrantly activated mammalian
target of rapamycin (mTOR) pathway in malignant PEComa led to
the use of mTOR inhibitors, such as sirolimus, for systemic therapy,
and promising anti-tumor effects have been demonstrated.5 Here,, National Taiwan University
, Taiwan.
ncology Society.
ociety. Production and hosting bywe report a rare case of PEComa arising from the gastrointestinal
tract and review the literature regarding this rare subtype of soft
tissue sarcoma.
2. Case report
A 60-year-old woman was in her usual state of health until late
2013 when she started to experience acid regurgitation and post-
prandial fullness. Esophagogastroduodenoscopy showed only
mild reﬂux esophagitis. Her symptoms failed to respond to symp-
tomatic treatments, including metoclopramide, antacids, and pro-
ton pump inhibitors, and progressed to easy vomiting over two
months and experienced unintentional weight loss of 4 kg in 1
week. There was no tarry stool or change in stool caliber. She was
examined at a local hospital, and initial examination with abdom-
inal ultrasonography revealed a large intra-abdominal tumor.
Computed tomography (CT) of the abdomen showed a
12  12  9 cm irregular mass in the left abdomen, with hetero-
geneous enhancement and mass effect on the adjacent structures.
No ascites or enlarged lymph nodes were seen on the CT image
(Fig. 1A). The results of all her laboratory tests were within the
normal range. A diagnosis of gastrointestinal stromal tumor (GIST),
leiomyosarcoma, or adenosarcoma was suspected. Surgical resec-
tion was suggested, and she was then referred to our hospital for
further management.
The patient was admitted to our gastrointestinal ward in
November 2013, and a follow-up abdominal ultrasonographyElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. (A) CT showed a large tumor, measuring up to 12 cm, in the left abdomen (B) Abdominal echo showed a heterogeneous and hypoechoic lesion with hypervascularity arising
from the small bowel wall.
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vascularity arising from the small bowel wall over the left upper
quadrant area (Fig. 1B). A tumor marker panel showed levels within
normal limits, as follows: carcinoembryonic antigen (CEA), 1.25 ng/
mL (normal range <5 ng/mL); CA 19-9, 6.34 U/mL (normal
range < 37 U/mL); CA 15-3, 6.8 U/mL (normal range 0e31 U/mL);
and CA-125, 7.1 U/mL (normal range 0e35 U/mL). A small bowel
GIST or leiomyosarcoma was suspected, and a general surgeon was
consulted for further resection.Fig. 2. (A) Epithelioid tumor cell radiating from staghorn-like vessels (100). (B) Admixtu
atypia (400). (D) Spindle cells with mitoses (400). (E) Tumor cells staining positive for sThe patient underwent surgery on December 2, 2013. A
13  13 cm elastic lobulated yellowish tumor, arising from the
upper jejunum with suspected local invasion into the transverse
colon and mesentery, was detected intraoperatively. Thus, small
bowel segmental resection and left hemicolectomy were per-
formed as radical treatment. Under gross examination by our
pathologist, the tumor was observed to arise from the jejunal
muscle layer with a focally jagged and inﬁltrative tumor border and
that it extended to the subserosa, serosa, and nearby mesocolon.re of spindle cells and epithelioid cells (200). (C) Epithelioid cells with mild nuclear
mooth muscle actin (100). (F) Tumor cells staining positive for Melan-A (100).
Table 1
Immunohistochemical results of two large series of PEComa.
PEComa of soft tissue/gynecological
origin (Folpe et al.1)
PEComa of GI tract
origin (Doyle et al.3)
Smooth Muscle
Actin
80% (20/25) 57% (20/35)
Desmin 36% (8/22) 74% (26/35)
Caldesmon N/A 50% (4/8)
HMB45 92% (22/24) 66% (23/35)
Melan-A 72% (13/18) 68% (23/24)
MiTF 50% (9/18) 60% (15/25)
TFE3 29% (5/17) 15% (3/20)
S-100 33% (8/24) 18% (5/27)
CK N/A 6% (1/15)
Vimetin 86% (12/14) N/A
KIT (CD117) 5% (1/20) 8% (2/25)
CD34 0% (0/7) N/A
N/A: not available.
Table 2
Risk stratiﬁcations in PEComa.
Factors associated with recurrence or metastasesa
Folpe
et al.1
Tumor size >5 cm, mitosis >1/50 HPF, necrosis, inﬁltrative growth
pattern, high nuclear grade and cellularity, vascular invasion
Doyle
et al.3
Mitosis >2/10 HPF, marked atypia, diffuse pleomorphism
Bleeker
et al.6
Tumor size >5 cmb, mitosis >1/50 HPFb, age, necrosis, high grade,
vascular invasion
a Statistically signiﬁcant by Fisher's exact test or univariate analysis.
b Signiﬁcant by multivariate analysis.
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uninvolved. The tumor was yellowish, elastic, and ﬁrm with areas
of necrosis. Microscopically, spindle cells arranged in interwoven
fascicles with occasional epithelioid cells were seen radiating from
staghorn-like vessels. The spindle cells contained elongated nuclei
and eosinophilic ﬁbrillary or granular cytoplasm. The epithelioid
cells contained a clear cytoplasmwith hyalinized stroma (Fig. 2A, B,
C). Mild to moderate nuclear pleomorphism and 6mitoses/10 high-
power ﬁeld (HPF) were seen (Fig. 2D). The surgical margins were
free of tumor involvement. Immunohistochemical studies showed
that the tumor cells were diffusely positive for smoothmuscle actin
(SMA) and h-caldesmon, focally positive for desmin and melan-A,
occasionally positive for MiTF, and negative for HMB-45, cytoker-
atin, CD117, DOG-1, S-100, CD34, CDK4, and MDM-2 (Fig. 2E, F).
Taken together, the tumor cells were positive for both myogenic
and melanocytic markers. A diagnosis of PEComa with spindle cell
predominance was conﬁrmed. Considering the highmitotic rate (6/
10 HPF) but limited cellular atypia and pleomorphism, the PEComa
was identiﬁed as a low-grade malignant tumor. Adjuvant chemo-
therapy or radiotherapy was not suggested owing to the lack of
evidence for clinical beneﬁts.
The patient was then regularly followed-up at our outpatient
clinic. However, abdominal CT in May 2014 revealed a right pelvic
mass measuring 3.46 cm. No other tumors were noted after the
restaging work-up. She underwent right pelvic tumor excision on
June 16, 2014. Further pathological examination conﬁrmed the
diagnosis of a recurrent PEComa. The mitosis count was 23/10 HPF
with moderate to marked pleomorphism. Systemic treatment was
not performed owing to the absence of residual tumors. Unfortu-
nately, a new left lower abdominal mass near the psoas muscle was
noted during subsequent follow-up. The tumor size was observed
to increase on serial CT images, and it resulted in left hydro-
nephrosis. A double J catheter was inserted accordingly. Because of
its unresectable status, systemic therapy with sirolimus (2 mg,
daily) for the recurrent PEComawas initiated in April 2015, with no
obvious adverse effects. Follow-up abdominal MRI on May 27
showed enlargement of the left lower retroperitoneal mass (from
7.2 cm to 9.8 cm), suggesting primary resistance to mTOR in-
hibitors. Thus, sirolimus was discontinued, and palliative resection
with local radiotherapy will be scheduled in the near future.
3. Discussion
PEComa is a rare subtype of mesenchymal tumor with charac-
teristic expression of both myogenic and melanocytic markers. It
harbors a wide range of morphologic appearances with the most
common ﬁnding of clear to lightly eosinophilic cells arranged in
nested, fascicular, or sheet-like patterns. The tumor cells are pre-
dominantly epithelioid, predominantly spindle-like, or an admix-
ture of both types and are surrounded by a delicate arborizing
capillary network.1 These unique tumor cells were thus named
“perivascular epithelioid cells” (PECs). The PEComa family of tu-
mors includes AML, LAM, and PEComa. AML is commonly seen as
an asymptomatic renal lesion with fat, muscle, and blood vessels.
Pulmonary LAM presents predominantly in young premenopausal
women with progressive multiple nodular and interstitial pulmo-
nary lesions, which may lead to respiratory failure. PEComa is an
epithelioid neoplasm typically arising in the gynecological tract,
retroperitoneum, GI tract, and soft tissue with variable clinical
behaviors.5,7
Deﬁnitive diagnosis of PEComa is mainly based on pathological
examination showing positivity for myogenic markersdincluding
SMA, desmin, and caldesmondand melanocytic markersdinclud-
ing HMB-45, melan-A, and MiTFdin the characteristic tumor cells
(Table 1). Generally, PEComas are diagnosed in middle-aged andpredominantly female patients. In one large pooled analysis of 234
cases of PEComa by Bleeker et al., the median age of PEComa pa-
tients was 43 years, and 79% of patients were women. The most
commonly reported tumor site is the uterus, followed by the skin
and the liver.6 Dolye et al. reported 35 cases of PEComa in the GI
tract, which is the largest reported series of GI PEComas. In contrast
to previous reports, PEComas in the GI tract do not exhibit gender
predilections, and over 90% of tumors are composed of purely or
predominantly epithelioid cells. The most common site for GI tract
PEComa is the colon followed by the small intestine.3
Most PEComas follow a relatively benign clinical course, but a
subset demonstrates aggressive behavior of local recurrence or
distant metastasis. Risk factors associated with recurrence or me-
tastases were proposed by several studies (Table 2). Folpe et al.
developed the ﬁrst and most widely accepted classiﬁcation utiliz-
ing the identiﬁed six unfavorable features (tumor size > 5 cm,
mitosis >1/50 HPF, necrosis, inﬁltrative growth pattern, high nu-
clear grade and cellularity, and vascular invasion). Malignant
PEComas are deﬁned as tumors with two or more unfavorable
features; benign PEComas, those with no unfavorable features; and
PEComas of uncertain malignant potential, those not fulﬁlling the
above conditions. The largest PEComa series reported by Bleeker
et al. showed that only primary tumor size 5 cm and high mitotic
rate (>1/50 HPF) were associated with recurrence.6 The series of
PEComas of the GI tract reported by Doyle et al. demonstrated that
marked atypia, diffuse polymorphism, andmitoses2/10 HPFwere
associated with metastasis.3 According to the above criteria, our
case should be classiﬁed as a malignant PEComa and it harbors a
risk of recurrence or metastasis.
The management of PEComa follows the same treatment prin-
ciples as other subtypes of soft tissue sarcoma. Surgical resection
remains the primary treatment modality. There is no consensus on
the administration of adjuvant treatment. Other treatment options,
including chemotherapy and radiotherapy, have been utilized at
T.-H. Liu et al. / Journal of Cancer Research and Practice 3 (2016) 14e18 17the discretion of physicians to minimize risk of recurrence. In order
to achieve complete surgical resection, neoadjuvant approaches
with chemotherapy or radiotherapy have also been performed.8
There is still no high-level evidence to support the clinical beneﬁt
of adjuvant or neoadjuvant therapy. Close surveillance plus
repeated resection remains one strategy. Long-term survival was
reported in a patient with recurrent PEComa receiving multiple
resections.9
Patients with tuberous sclerosis complex or
lymphangioleiomyomatosis-related AML were shown to harbor
mutations of tuberous sclerosis genes, including the harmatin gene
(TSC1) and the tuberin gene (TSC2). The TSC1/TSC2 complex in-
hibits the downstream Rheb-GTP, which can activate the mTOR
complex and lead to phosphorylation of S6 kinase, protein syn-
thesis, and cell growth. Aberrations in TSC1 or TSC2 result in loss of
function of the complex and release of inhibition of Rheb-GTP,
which then aberrantly overactivates the mTOR pathway.7,10 mTOR
inhibitors, such as sirolimus or temsirolimus, are thus hypothesized
to possess clinical activity in neoplasms with loss of TSC1 or TSC2
expression. The pivotal study by Bissler et al. demonstrated the
efﬁcacy of sirolimus in reducing the size of AMLs and improving
pulmonary function in patients with pulmonary LAM.7 There is also
evidence of mTOR pathway overactivation in PEComa,11,12 and
sirolimus was shown to be effective against malignant PEComa.5
PEComa cells are usually immunohistochemically positive for
phospho-S6 and phospho-p70S6K and negative for TSC2 and
phopho-Akt.11 The level of phospho-S6 expressionwas proposed to
be a predictive marker of early tumor response to mTOR
inhibitors.13
In patients with malignant PEComa receiving sirolimus or
temsirolimus, the largest case series reported a response rate of up
to 50% with a median treatment duration of 128 days. Treatment
toxicity is generally mild and manageable, with oral mucositis as
the most commonly occurring adverse effect. The reported 1-year
survival rate was 78.8% with a median overall survival of 2.4
years.14,15 Primary or secondary resistance to mTOR inhibitors was
reported, but the exact mechanism is largely unknown.16 Possible
resistance mechanisms, as seen in other tumors treated with mTOR
inhibitors, include mutations in mTOR, feedback loop activation of
the PI3K/Akt pathway, increased activation of the alternative ERK/
MAPK pathway, decreased expression of 4E-BP1, or overexpression
of downstream eIF4E.17
Conventional chemotherapy has little efﬁcacy in malignant
PEComa, despite reports of cases showing clinical response.18
Interestingly, expression of estrogen and progesterone receptors
has also been noted in PEComas with predominant spindle
morphology.16 Letrozole, an aromatase inhibitor, has been reported
to have a favorable and sustained effect in PEComa.19 In addition to
systemic treatments, aggressive local treatments, such as radio-
therapy and surgical resection, may still play some roles in man-
aging metastatic PEComa. Long-term disease control achieved by
repeated metastasectomy was also reported.9
TFE3 gene fusion has been demonstrated in several types of
neoplasia, including alveolar soft part sarcoma (ASPS) and pediatric
renal cell carcinoma.20 Recently, a subset of PEComa has also been
shown to harbor TFE3 gene rearrangement.21,22 This subset of
rearranged PEComa is distinctive from their non-rearranged
counterpart in several aspects. They typically comprise pure
epithelioid cells arranged in an alveolar pattern and stain strongly
for TFE3 and HMB-45 while expressing minimal muscle markers.23
Their morphology bears a similarity to ASPS under light micro-
scopy, and the differential diagnosis can be made on the basis that
ASPS is negative for HMB-45 and Melan-A and harbors a unique
ASPSCR1-TFE3 translocation.23,24 TSC2 is not inactivated in this
subset of PEComa, which theoretically implies that treatment withan mTOR inhibitor will not be effective.20,25 The presence of this
subset of rearranged PEComa may serve to partly explain the pri-
mary resistance to mTOR inhibitors. However, the primary resis-
tance seen in our case is unlikely to be explained by TFE3 gene
rearrangement considering the tumor's positivity for muscle
markers and the predominant spindle pattern.
In summary, we report a rare case of PEComa arising from the GI
tract. The diagnosis of malignant PEComa is based on pathologically
unique features. Localized PEComa should be completely resected.
Overactivation of the mTOR pathway may be present in PEComa,
and mTOR inhibitors are currently the recommended systemic
treatment in unresectable or metastatic malignant PEComa.
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